{"id":545489,"date":"2021-05-31T14:00:02","date_gmt":"2021-05-31T14:00:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=545489"},"modified":"2021-05-31T14:00:02","modified_gmt":"2021-05-31T14:00:02","slug":"xerostomia-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/xerostomia-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_545489.html","title":{"rendered":"Xerostomia Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1622460387.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Xerostomia Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1622460387.png\" alt=\"Xerostomia Market Analysis, Market Size, Trends, Epidemiology, Leading Companies And Therapies | DelveInsight\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>DelveInsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight&#8217;s &#8220;Xerostomia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<\/div>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight has launched a new report on &#8220;X<strong>erostomia-Market Insights, Epidemiology, and Market Forecast-2030<\/strong>&rdquo;.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">DelveInsight&rsquo;s &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\"><strong>Xerostomia&ndash;Market Insights, Epidemiology, and Market Forecast-2030<\/strong><\/a>&rdquo; report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Some of the key facts of the Report:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the study prevalence of xerostomia was 16% (patients with XI scores 10) and the prevalence of hyposalivation was 31% (patients with stimulated salivary flow rate 0.7 ml\/min).<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the observation that the prevalence of xerostomia ranged from 17% to 40% among community-dwelling elders and 20% to 72% among institutionalized elders. The prevalence of hyposalivation ranged from 15% to 23% in the community-dwelling elders and 17% to 50% among institutionalized elders<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">According to the observation, the prevalence of xerostomia ranged from 0.9% to 64.8%. The majority of data collected for these studies was in Scandinavia (most patients age greater than 50, the rest being over 18).&nbsp;<\/p>\n<\/li>\n<\/ul>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Key benefits of the report:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1.The Xerostomia market report covers a descriptive overview and comprehensive insight of the Xerostomia epidemiology and Xerostomia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2.The Xerostomia market report provides insights into the current and emerging therapies.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3.Xerostomia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4.The Xerostomia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Xerostomia market.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Request for sample pages:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market<\/a><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/metabolic-acidosis-market\"><br \/><\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia: Overview<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Xerostomia is defined as the &ldquo;complaint of oral dryness&rdquo;. It can occur due to inadequate salivary secretion secondary to abnormal function of the salivary glands, which is categorized as &ldquo;true&rdquo; xerostomia; however, most patients with xerostomia often do not have objective signs of hyposalivation.&ldquo;Symptomatic&rdquo; xerostomia or &ldquo;pseudo&rdquo; xerostomia refers to oral dryness despite normal salivary gland function.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">Patients with xerostomia can have clinical manifestations of difficulty in swallowing, chewing, and\/or speaking and can present with a burning mouth, halitosis, altered taste, dry buccal mucosa, glossitis, cracked and peeled lips, oral candidiasis, and dental caries despite good oral hygiene.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The key players involved in the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/xerostomia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">Xerostomia market<\/a>:<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">Lubris BioPharma<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">MeiraGTx<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>The launch of the emerging therapies is expected to significantly impact the&nbsp; Xerostomia treatment scenario in the upcoming years:-<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Drug covered<\/strong><\/p>\n<ol style=\"text-align: justify;\">\n<li dir=\"ltr\">\n<p dir=\"ltr\">LBS020<\/p>\n<\/li>\n<li dir=\"ltr\">\n<p dir=\"ltr\">AAV-AQP1<\/p>\n<\/li>\n<\/ol>\n<p style=\"text-align: justify;\"><strong>Request a free sample report @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=kpr\" target=\"_blank\">https:\/\/www.delveinsight.com\/sample-request\/xerostomia-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Table of Contents<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">1. Report Introduction<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">4. Xerostomia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">5. Xerostomia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">6. Xerostomia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">7. Xerostomia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">8. Country-Specific Patient Population of Xerostomia&nbsp;<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">9. Xerostomia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">10. Unmet Needs<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">11. Xerostomia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">12. Xerostomia Market Outlook<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">13. Country-Wise Xerostomia Market Analysis (2017&ndash;2030)<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">17. Appendix<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">18. Xerostomia Report Methodology<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Related Reports:<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia-Pipeline Insights, 2021<\/strong><\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\">&#8220;Xerostomia-Pipeline Insight, 2021&#8221; report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Xerostomia market. A detailed picture of the Xerostomia pipeline landscape is provided, which includes the disease overview and Xerostomia treatment guidelines.<\/p>\n<p style=\"text-align: justify;\" dir=\"ltr\"><strong>Xerostomia-Epidemiology Forecast to 2030<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight&#8217;s &#8216;Xerostomia-Epidemiology Forecast to 2030&#8217; report delivers an in-depth understanding of the disease, historical and forecasted Xerostomia{;l epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56431.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Kritika Rehani<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=xerostomia-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=xerostomia-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight Business Research LLP DelveInsight&#8217;s &#8220;Xerostomia &#8211; Market Insights, Epidemiology, and Market Forecast-2030&#8221; report delivers an in-depth understanding of the Xerostomia, historical and forecasted epidemiology as well as the Xerostomia market trends in the United States, EU5 (Germany, Spain, Italy, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/xerostomia-market-analysis-market-size-trends-epidemiology-leading-companies-and-therapies-delveinsight_545489.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,435,405,406,404],"tags":[],"class_list":["post-545489","post","type-post","status-publish","format-standard","hentry","category-Business","category-Europe","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-US"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545489","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=545489"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/545489\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=545489"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=545489"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=545489"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}